Abstract
Objective We analyzed in patients with essential tremor (ET) the Thr105Ile polymorphism of the Histamine N-methyltransferase (HNMT) enzyme that is associated to Parkinson’s disease (PD) risk. Methods Leukocytary DNA from 204 ET patients and a control group of 295 unrelated healthy individuals was studied for the nonsynonymous HNMT Thr105Ile polymorphism by using amplification-restriction analyses. Results Patients with ET showed a higher frequency of homozygous HNMT 105Thr genotypes leading to high metabolic activity (p < 0.015) with a statistically significant gene-dose effect, as compared to healthy subjects. These findings were independent of gender, and of tremor localization, but the association of the HNMT polymorphism is more prominent among patients with late-onset ET (p < 0.007). Conclusion These results, combined with previous findings indicating alterations in the frequency for the HNMT Thr105Ile polymorphism in patients with PD, suggest that alterations of histamine homeostasis in the SNC are associated with the risk of movement disorders.
Similar content being viewed by others
References
Agundez, J. A., Jimenez-Jimenez, F. J., Tejeda, R., Ledesma, M. C., Orti-Pareja, M., Gasalla, T., et al. (1997). CYP2D6 polymorphism is not associated with essential tremor. European Neurology, 38, 99–104.
Agundez, J. A., Luengo, A., Herraez, O., Martinez, C., Alonso-Navarro, H., Jimenez-Jimenez, F. J., et al. (2007) Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson’s disease. Neuromolecular Medicine, 10(1), 10–16.
Alonso-Navarro, H., Martinez, C., Garcia-Martin, E., Benito-Leon, J., Garcia-Ferrer, I., Vazquez-Torres, P., et al. (2006). CYP2C19 polymorphism and risk for essential tremor. European Neurology, 56, 119–123.
Anichtchik, O. V., Rinne, J. O., Kalimo, H., & Panula, P. (2000). An altered histaminergic innervation of the substantia nigra in Parkinson’s disease. Experimental Neurology, 163, 20–30.
Benito-Leon, J., Bermejo-Pareja, F., & Louis, E. D. (2005). Incidence of essential tremor in three elderly populations of central Spain. Neurology, 64, 1721–1725.
Benito-Leon, J., & Louis, E. D. (2007). Clinical update: Diagnosis and treatment of essential tremor. Lancet, 369, 1152–1154.
Brennan, P. (2002). Gene-environment interaction and aetiology of cancer: What does it mean and how can we measure it? Carcinogenesis, 23, 381–387.
Busenbark, K. L., Huber, S. J., Greer, G., Pahwa, R., & Koller, W. C. (1992). Olfactory function in essential tremor. Neurology, 42, 1631–1632.
Coelho, M. H., Silva, I. J., Azevedo, M. S., & Manso, C. F. (1991). Decrease in blood histamine in drug-treated parkinsonian patients. Molecular and Chemical Neuropathology, 14, 77–85.
Daly, A. K., & Day, C. P. (2001). Candidate gene case-control association studies: Advantages and potential pitfalls. British Journal of Clinical Pharmacology, 52, 489–499.
Deuschl, G., Bain, P., & Brin, M. (1998). Consensus statement of the movement disorder society on tremor. Ad Hoc Scientific Committee. Movement Disorders, 13(Suppl. 3), 2–23.
Dogu, O., Sevim, S., Camdeviren, H., Sasmaz, T., Bugdayci, R., Aral, M., et al. (2003). Prevalence of essential tremor: Door-to-door neurologic exams in Mersin Province, Turkey. Neurology, 61, 1804–1806.
Findley, L. J. (2000). Epidemiology and genetics of essential tremor. Neurology, 54, S8–S13.
Garcia-Martin, E., Garcia-Menaya, J., Sanchez, B., Martinez, C., Rosendo, R., & Agundez, J. A. (2007). Polymorphisms of histamine-metabolizing enzymes and clinical manifestations of asthma and allergic rhinitis. Clinical and Experimental Allergy, 37, 1175–1182.
Gulcher, J. R., Jonsson, P., Kong, A., Kristjansson, K., Frigge, M. L., Karason, A., et al. (1997). Mapping of a familial essential tremor gene, FET1, to chromosome 3q13. Nature Genetics, 17, 84–87.
Higgins, J. J., Jankovic, J., Lombardi, R. Q., Pucilowska, J., Tan, E. K., Ashizawa, T., et al. (2003). Haplotype analysis of the ETM2 locus in familial essential tremor. Neurogenetics, 4, 185–189.
Higgins, J. J., Lombardi, R. Q., Pucilowska, J., Jankovic, J., Tan, E. K., & Rooney, J. P. (2005). A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology, 64, 417–421.
Higgins, J. J., Loveless, J. M., Jankovic, J., & Patel, P. I. (1998). Evidence that a gene for essential tremor maps to chromosome 2p in four families. Movement Disorders, 13, 972–977.
Illarioshkin, S. N., Rakhmonov, R. A., Ivanova-Smolenskaia, I. A., Brice, A., Markova, E. D., Miklina, N. I., et al. (2002). Molecular genetic analysis of essential tremor. Genetika, 38, 1704–1709.
Jimenez-Jimenez, F. J., de Toledo-Heras, M., Alonso-Navarro, H., Ayuso-Peralta, L., Arevalo-Serrano, J., Ballesteros-Barranco, A., et al. (2007). Environmental risk factors for essential tremor. European Neurology, 58, 106–113.
Josephs, K. A., Matsumoto, J. Y., & Ahlskog, J. E. (2006). Benign tremulous parkinsonism. Archives of Neurology, 63, 354–357.
Khan, N. L., Jain, S., Lynch, J. M., Pavese, N., Abou-Sleiman, P., Holton, J. L., et al. (2005). Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson’s disease: Clinical, pathological, olfactory and functional imaging and genetic data. Brain, 128, 2786–2796.
Kim, S. H., Krapfenbauer, K., Cheon, M. S., Fountoulakis, M., Cairns, N. J., & Lubec, G. (2002). Human brain cytosolic histamine-N-methyltransferase is decreased in Down syndrome and increased in Pick’s disease. Neuroscience Letters, 321, 169–172.
Koller, W. C., Busenbark, K., & Miner, K. (1994). The relationship of essential tremor to other movement disorders: Report on 678 patients. Essential Tremor Study Group. Annals of Neurology, 35, 717–723.
Langlais, P. J., Zhang, S. X., Weilersbacher, G., Hough, L. B., & Barke, K. E. (1994). Histamine-mediated neuronal death in a rat model of Wernicke’s encephalopathy. Journal of Neuroscience Research, 38, 565–574.
Louis, E. D. (2005). Essential tremor. Lancet Neurology, 4, 100–110.
Louis, E. D., Honig, L. S., Vonsattel, J. P., Maraganore, D. M., Borden, S., & Moskowitz, C. B. (2005). Essential tremor associated with focal nonnigral Lewy bodies: A clinicopathologic study. Archives of Neurology, 62, 1004–1007.
Louis, E. D., & Jurewicz, E. C. (2003). Olfaction in essential tremor patients with and without isolated rest tremor. Movement Disorders, 18, 1387–1389.
Louis, E. D., Marder, K., Cote, L., Wilder, D., Tang, M. X., Lantigua, R., et al. (1996). Prevalence of a history of shaking in persons 65 years of age and older: Diagnostic and functional correlates. Movement Disorders, 11, 63–69.
Martinez, C., Garcia-Martin, E., Alonso-Navarro, H., Jimenez-Jimenez, F. J., Benito-Leon, J., Garcia-Ferrer, I., et al. (2007). Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. Neuromolecular Medicine, 9, 195–204.
Mjones, H. (1949). Paralysis agitans: A clinical genetic study. Acta Psychiatrica et Neurologica Scandinavica, 54, 1–195.
Ondo, W. G., & Lai, D. (2005). Olfaction testing in patients with tremor-dominant Parkinson’s disease: Is this a distinct condition? Movement Disorders, 20, 471–475.
O’Suilleabhain, P. E. (2006). Parkinson disease with severe tremor but otherwise mild deterioration. Archives of Neurology, 63, 321–322.
Pigullo, S., Di Maria, E., Marchese, R., Bellone, E., Gulli, R., Scaglione, C., et al. (2003). Essential tremor is not associated with alpha-synuclein gene haplotypes. Movement Disorders, 18, 823–826.
Prell, G. D., & Green, J. P. (1991). Histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid. Agents and Actions. Supplements, 33, 343–363.
Preuss, C. V., Wood, T. C., Szumlanski, C. L., Raftogianis, R. B., Otterness, D. M., Girard, B., et al. (1998). Human histamine N-methyltransferase pharmacogenetics: Common genetic polymorphisms that alter activity. Molecular Pharmacology, 53, 708–717.
Rajput, A. H., Rozdilsky, B., Ang, L., & Rajput, A. (1993). Significance of parkinsonian manifestations in essential tremor. Canadian Journal of Neurological Sciences, 20, 114–117.
Shahed, J., & Jankovic, J. (2007). Exploring the relationship between essential tremor and Parkinson’s disease. Parkinsonism & Related Disorders, 13, 67–76.
Skipper, L., Shen, H., Chua, E., Bonnard, C., Kolatkar, P., Tan, L. C., et al. (2005). Analysis of LRRK2 functional domains in nondominant Parkinson disease. Neurology, 65, 1319–1321.
Tan, E. K., Matsuura, T., Nagamitsu, S., Khajavi, M., Jankovic, J., & Ashizawa, T. (2000). Polymorphism of NACP-Rep1 in Parkinson’s disease: An etiologic link with essential tremor? Neurology., 54, 1195–1198.
Thoburn, K. K., Hough, L. B., Nalwalk, J. W., & Mischler, S. A. (1994). Histamine-induced modulation of nociceptive responses. Pain, 58, 29–37.
Acknowledgments
We are thankful to Ms. Diana Herrero for technical assistance and to Prof. James McCue for assistance in language editing. This work was supported in part by Grants SAF 2003-00967 from Ministerio de Ciencia y Tecnología, FIS 05/1056, 06/1252 and RETICS 07/0064/0016 from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ledesma, M.C., García-Martín, E., Alonso-Navarro, H. et al. The Nonsynonymous Thr105Ile Polymorphism of the Histamine N-Methyltransferase is Associated to the Risk of Developing Essential Tremor. Neuromol Med 10, 356–361 (2008). https://doi.org/10.1007/s12017-008-8040-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-008-8040-3